Phase I studies of porfiromycin (NSC—56410) in solid tumors
✍ Scribed by Dr. Theodor B. Grage; Arthur J. Weiss; William Wilson; Vernon Reynolds
- Publisher
- John Wiley and Sons
- Year
- 1975
- Tongue
- English
- Weight
- 354 KB
- Volume
- 7
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and
BACKGROUND. CI-958 is a synthetic intercalating agent of a new chemical class, the benzopyranoindazoles, with promising preclinical activity. Its mechanism of action is thought to be stabilization of the cleavable complex of DNA with topoisomerase II, as well as DNA helicase blockade. It is thought
## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma